The global cell and gene therapy market size was valued at USD 27.38 billion in 2025 and is projected to grow from USD 33.85 billion in 2026 to USD 184.60 billion by 2034, registering a CAGR of 23.62% during the forecast period from 2026 to 2034. North America dominated the cell and gene therapy market with a market share of 46.8% in 2025.
Cell and gene therapy includes advanced medical treatments that modify or replace genes or use living cells to treat, prevent, or potentially cure diseases. These therapies are widely used for genetic disorders, certain cancers, and rare diseases by targeting the root cause of illness. Demand is growing due to rapid advances in biotechnology, increasing clinical research, and rising investments in personalized and regenerative medicine.
Download a Free Sample To learn more about this report,
Growing Expansion of Personalized Cell and Gene Therapies for Rare Diseases
Cell and Gene Therapy Market trends are being driven by the growing use of personalized treatments for cancer, rare genetic disorders, and inherited diseases. Healthcare companies are increasing investments in cell and gene therapy research to develop one-time treatments that target the root cause of disease instead of only managing symptoms. Rising regulatory approvals, expanding clinical trials, and improvements in manufacturing technologies are helping bring these advanced therapies closer to patients. The increasing collaboration between biotechnology companies, research institutes, and healthcare providers is supporting cell and gene therapy market growth as demand for innovative treatment options continues to rise.
Rising Innovation in Gene Editing and Automated Manufacturing Technologies
Cell and Gene Therapy Market trends are also being influenced by rapid advances in gene editing tools, automated manufacturing, and viral vector production. Companies are developing next-generation platforms that improve treatment precision, reduce production timelines, and enhance the scalability of commercial manufacturing. Automation and digital process monitoring are also helping manufacturers maintain product quality while lowering production costs. These advancements are strengthening cell and gene therapy market share by enabling faster development of innovative therapies and supporting broader adoption across oncology, rare diseases, and regenerative medicine.
Rising Demand for Personalized Medicine and Advanced Therapies
The cell and gene therapy market is growing rapidly as healthcare providers focus on treating diseases at their root cause rather than only managing symptoms. Cell and gene therapies are showing promising results in treating cancer, rare genetic disorders, blood diseases, and certain autoimmune conditions. Increasing approvals of innovative therapies, rising investment in biotechnology research, and expanding clinical trials are strengthening cell and gene therapy market demand. Growing support from regulatory agencies for advanced therapies is also driving market growth.
High Treatment Costs and Complex Manufacturing
The cell and gene therapy market faces challenges because developing and manufacturing these therapies is highly complex and expensive. The production process requires specialized facilities, advanced technologies, and strict quality control, which increases overall treatment costs. In addition, storage, transportation, and handling requirements make large-scale commercialization more challenging.
Expansion of Clinical Research and New Therapeutic Applications
The cell and gene therapy market offers strong opportunities as researchers continue to explore new treatments for neurological disorders, cardiovascular diseases, diabetes, and other chronic conditions. Growing collaborations between pharmaceutical companies, biotechnology firms, and research institutions are accelerating the development of innovative therapies. Improvements in gene-editing technologies, including CRISPR-based approaches, are expected to strengthen cell and gene therapy market share over the coming years.
Ensuring Long-Term Safety and Expanding Patient Access
The cell and gene therapy market continues to face challenges in proving long-term safety, maintaining consistent manufacturing quality, and making treatments more affordable. Companies must conduct extensive clinical studies while meeting strict regulatory standards before bringing new therapies to market. Improving reimbursement policies and expanding treatment access remain important priorities. Continued investment in manufacturing innovation, clinical research, and global healthcare partnerships will be essential for long-term market growth.
CAR-T Cell Therapy Segment Dominated the Market with 22.4% Share in 2025
The CAR-T cell therapy segment dominated the global cell and gene therapy market with a 22.4% share in 2025. CAR-T therapy has become one of the most successful cell-based treatments for blood cancers because it delivers highly targeted immune responses and has shown promising long-term clinical outcomes. Increasing regulatory approvals and expanding clinical applications continue to strengthen the segment's leading position.
The cell therapy, gene therapy, CAR-NK, B-cell therapy, and other therapy segments are also witnessing steady growth as researchers develop advanced treatments for cancer, rare diseases, and genetic disorders. Cell therapy is gaining wider adoption for regenerative medicine, while gene therapy is expanding as it offers the potential to treat diseases at the genetic level. CAR-NK therapies are attracting attention due to their promising safety profile, and B-cell therapies continue to support treatment for hematological conditions.
Within the CAR-T segment, autologous CAR-T remains widely used because it uses the patient's own immune cells to reduce the risk of rejection. The allogeneic CAR-T segment is growing rapidly as manufacturers develop off-the-shelf therapies that can improve treatment availability and reduce manufacturing time. Within gene therapy, viral vectors continue to dominate delivery systems, with adeno-associated virus (AAV) and lentiviral vectors being widely used for targeted gene delivery, while other vector technologies continue to evolve through ongoing research and innovation.
Request Customizationto receive a tailored report.
Oncology Segment Dominated the Market with 48.7% Share in 2025
The oncology segment dominated the global cell and gene therapy market with a 48.7% share in 2025. Cell and gene therapies are increasingly used in cancer treatment because they offer highly targeted approaches that improve treatment outcomes while reducing damage to healthy tissues. The growing number of cancer clinical trials and product approvals continues to support this segment's leading position.
The immunology, musculoskeletal, dermatology, and neurology segments are also growing steadily as advanced therapies are being developed for autoimmune disorders, tissue repair, skin diseases, and neurological conditions. Researchers continue to expand the use of gene editing and regenerative medicine across these therapeutic areas.
The others segment also continues to expand as cell and gene therapies are investigated for rare diseases, inherited disorders, and additional chronic conditions. Continuous innovation and increasing investment in regenerative medicine are expected to support growth across all application areas.
Biopharmaceutical & Biotechnology Companies Segment Dominated the Market with 49.5% Share in 2025
The biopharmaceutical & biotechnology companies segment dominated the global cell and gene therapy market with a 49.5% share in 2025. These companies are leading the development of innovative cell and gene therapies through significant investments in research, clinical trials, and commercialization. Their strong focus on precision medicine and advanced biologics continues to drive market growth.
The pharmaceutical companies segment is also growing steadily as major drug manufacturers expand their regenerative medicine portfolios through strategic partnerships, acquisitions, and internal research programs. Their global manufacturing capabilities and regulatory expertise are helping accelerate the commercialization of advanced therapies.
The CDMOs/CMOs segment is expanding rapidly as therapy developers increasingly outsource manufacturing to specialized organizations with expertise in cell processing, viral vector production, and quality control. The others segment also contributes to market growth through academic institutions, research organizations, and emerging biotechnology companies that continue to advance innovation in cell and gene therapy.
Speak to an Analystto discuss market opportunities.
North America cell and gene therapy market accounted for 46.8% of the global market, reaching USD 12.81 billion in 2025, and is projected to grow at a CAGR of 17.94% during the forecast period. The market is growing rapidly because of increasing investment in advanced biologics, strong clinical trial activity, and rising approvals for cell and gene therapies. Well-established biotechnology companies and supportive regulatory frameworks are also driving regional growth.
The U.S. market was valued at USD 10.89 billion in 2025, making it the largest contributor in North America. Strong investment in biotechnology, increasing clinical research, and growing adoption of advanced therapies for cancer and rare diseases continue to drive market growth.
Canada's market reached USD 1.92 billion in 2025. Expanding life science research, increasing government support for biotechnology, and rising clinical trial activity continue to support steady market growth.
Unlock Regional Insightsto access country-level data, & regional trends.
Europe cell and gene therapy market accounted for 27.4% of the global market, reaching USD 7.50 billion in 2025, and is expected to register a CAGR of 18.16% during the forecast period. Rising investment in precision medicine, growing biotechnology innovation, and increasing collaboration between research institutes and pharmaceutical companies are supporting market growth. The region is also expanding manufacturing capacity for advanced therapies.
Germany's market accounted for USD 2.18 billion in 2025. Strong biotechnology research, increasing clinical development, and growing investment in advanced therapy manufacturing continue to support market growth.
The UK market was valued at USD 1.50 billion in 2025. Expanding research in regenerative medicine, increasing clinical trials, and strong government support for life sciences continue to contribute to market growth.
Asia Pacific cell and gene therapy market accounted for 18.6% of the global market, valued at USD 5.09 billion in 2025, and is projected to register a CAGR of 21.48% during the forecast period. Growing biotechnology investments, expanding healthcare infrastructure, and increasing research into regenerative medicine are driving market growth across the region. Government funding and rising demand for innovative treatments are also creating strong opportunities.
Japan's market generated USD 0.92 billion in 2025. Strong research capabilities, supportive regulatory policies, and increasing development of regenerative therapies continue to support market growth.
China's market accounted for USD 2.65 billion in 2025, representing the largest share within Asia Pacific. Rapid expansion of biotechnology companies, increasing clinical trials, and significant investment in advanced healthcare technologies continue to drive market growth.
Latin America cell and gene therapy market accounted for 4.2% of the global market, reaching USD 1.15 billion in 2025, and is projected to grow at a CAGR of 16.87% during the forecast period. Improving healthcare infrastructure, increasing biotechnology research, and growing access to advanced therapies are supporting market growth across the region.
Brazil's market reached USD 0.59 billion in 2025. Rising investment in healthcare research, expanding biotechnology capabilities, and increasing collaboration with global pharmaceutical companies continue to create growth opportunities.
Middle East & Africa cell and gene therapy market accounted for 3% of the global market, totaling USD 0.82 billion in 2025, and is anticipated to grow at a CAGR of 15.92% during the forecast period. Increasing investment in healthcare innovation, expanding biotechnology infrastructure, and growing focus on advanced treatment options are supporting market growth across the region.
The UAE market was valued at USD 0.30 billion in 2025. Government investment in advanced healthcare, growing biotechnology initiatives, and increasing adoption of precision medicine continue to support market growth.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Her work focuses on assessing treatment landscapes, outsourcing models, technology adoption, market access dynamics, regulatory developments, and competitive positioning across healthcare and life sciences industries. Debashree has consistently supported organizations in understanding market gaps, evaluating revenue potential, developing market entry strategies, and shaping expansion plans across complex and fast evolving healthcare markets.
With a strong analytical foundation and structured research approach, she excels at synthesizing large datasets, stakeholder inputs, and market signals into actionable insights that guide strategic decision making. Her healthcare expertise enables her to connect clinical, commercial, and operational developments with business opportunities, helping stakeholders anticipate shifts and capitalize on emerging growth areas. Debashree’s consulting oriented mindset and deep healthcare industry understanding make her a trusted advisor to businesses navigating dynamic and rapidly evolving healthcare markets.
Rotavirus Vaccines Market Size, Share, Growth, Analysis, 2034
Proton Therapy Market Size, Share, Growth, Analysis, Report, 2034
Urinalysis Market Size, Share, Growth, Analysis, Report, 2034
Test Strip Market Size, Share, Growth, Analysis, Report, 2034
Rare Biomarkers Specimen Collection and Stabilization Market Size, 2034
Protein Therapeutics Market Size, Share, Growth, Analysis, 2034
We are featured on:
sales@straitsresearch.com